[
    [
        {
            "time": "2018-10-28",
            "original_text": "【医药-天坛生物(600161)】江琦、赵磊：2018Q3点评：血制品业务稳健增长，季度环比盈利改善-20181028",
            "features": {
                "keywords": [
                    "天坛生物",
                    "血制品业务",
                    "稳健增长",
                    "季度环比",
                    "盈利改善"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【医药-天坛生物(600161)】江琦、赵磊：2018Q3点评：血制品业务稳健增长，季度环比盈利改善-20181028",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 2
            }
        }
    ]
]